PROfound Study – PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations – Maha Hussain

Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it’s intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate…

Read the full article here

Related Articles